Filing Details

Accession Number:
0000905718-21-000760
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-06-07 08:53:45
Reporting Period:
2021-06-03
Accepted Time:
2021-06-07 08:53:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1637715 Reneo Pharmaceuticals Inc. RPHM Pharmaceutical Preparations (2834) 472309515
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1784138 Bali Muralidhar C/O Reneo Pharmaceuticals, Inc.
12230 El Camino Real, Suite 230
San Diego CA 92130
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-06-03 12,100 $9.25 1,877,375 No 4 P Indirect By Abingworth Bioventures 8 LP
Common Stock Acquisiton 2021-06-04 257 $9.42 1,877,632 No 4 P Indirect By Abingworth Bioventures 8 LP
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Abingworth Bioventures 8 LP
No 4 P Indirect By Abingworth Bioventures 8 LP
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.08 to $9.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.30 to $9.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
  3. The shares are held by Abingworth Bioventures 8 LP ("Abingworth 8"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the "General Partners"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8.
  4. Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.